Navigation Links
Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
Date:10/15/2007

equencing technology and current sample preparation methods by providing an adaptable, massively parallel method for selective enrichment of genomic regions of interest. Roche NimbleGen's sequence capture technology enables high-performance targeting of thousands of specific genes or loci using a single microarray hybridization-based enrichment process. The Baylor study(1) used Roche's Genome Sequencer FLX(TM) System to quickly and affordably sequence the enriched genomic regions for downstream analysis. 454 Sequencing technology is ideal for this targeted sequencing approach because of its long read lengths and highly accurate reads.

"This new technology will replace polymerase chain reaction (PCR) for many purposes," said Gibbs. "If the aim is to sequence a whole genome for everybody, this is a huge step in that direction."

The Nature Methods paper published by Baylor(1) demonstrates that the sequence capture process is simpler, more accurate, more efficient and more cost-effective than the multiplex PCR that was previously used to prepare genomic samples for sequencing. In one experiment, more than 6,700 exons (the part of the genetic code that together form genes), were enriched and analyzed, as well as contiguous genomic regions of up to 5 million bases. Using the old technology this would have taken at least six months.

"We're delighted to have an opportunity to collaborate with scientists at Baylor HGSC on the development of this breakthrough technology," said Dr. Stan Rose, President of Roche NimbleGen. "The combination of these two Roche technologies-NimbleGen and 454-has the potential to transform the market for DNA sequence analysis."

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary fo
'/>"/>

SOURCE Roche NimbleGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount System for Automated Cell Counting at AACR
2. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
3. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
4. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
10. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
11. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating th...linically meaningful extension of progression-free...mab to attack both the inside and,outside of the H...ade, -- Data demonstrating activity of TYKERB alo...ple lines of trastuzumab and chemotherapy, LONDON...
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 1PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 2CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 1CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 2TOFUTTI Announces 2007 Results 16776 1TOFUTTI Announces 2007 Results 16776 2TOFUTTI Announces 2007 Results 16776 3TOFUTTI Announces 2007 Results 16776 4TOFUTTI Announces 2007 Results 16776 5Testosterone Spray Improves Sexual Satisfaction in Women 16771 1Testosterone Spray Improves Sexual Satisfaction in Women 16771 2
(Date:5/16/2008)... that Primary care medicine is in a precipitous de...merican College of Physicians (ACP), today joined...sumers to issue a call for comprehensive reforms t...nd other primary care physicians. , During a pa...ne in the U.S., Dr. Dale and other panelists spoke...
(Date:5/16/2008)...ervices for Frail Seniors and People With,Disabili...ire/ -- Thousands of,homecare workers across the s...proposed cuts to hours of service, wages and benef...ulnerable workers and the,people they serve deeper...rvices for seniors and people with disabilities fr...
(Date:5/16/2008)...alth Institute with 10,000 Sensual O Condom Packs ...Mansion Fundraiser, LOS ANGELES, May 16 /PRNewswi... B artist J Kwon known best for his hit song "Ever...ng the Urban Health Institute (UHI) with,10,000 Se... The donation is,being made to promote the launch ...
(Date:5/16/2008)... who would benefit most from chemo after surgery, ... News) -- A panel of 15 genes may help determine w... cancer will experience a recurrence and, therefor... shows. , By extension, the same genetic signa...ve forms of the cancer who would be able to forego...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...t deadly form of skin cancer , advanced melanoma c...ts with tumor proteins, say researchers according ...ect vaccinating patients with tumor antigens (call...e cells, which are known as killer T-cells. It was...
...iscovery could help prevent complications for preg...lampsia. Preeclampsia typically develops after the...gh blood pressure, // edema, and protein in the u...here a sharp rise in blood pressure causes the mot...
... killer cells are part of the body’s immune system...ome cancers, particularly leukemia. A new study sh...emia // patients may lie in artificially stimulat...member. Researchers say this method could help tr...
...hers say they have found that stem cell therapy is...uring the study injecting stem cells from one pig'...ig's damaged heart muscle restored the heart's fun...hers studied 14 pigs, whose circulatory systems ar...
Other Medicine News:
... Substitutes a natural alternative to autografts. ... but such grafts may introduce the risk of immune ... has developed the Pro Osteon family of bone graft...s a broad range of bone grafting alternatives that...
Schuknecht-Weitlaner retractor, sharp, angled arms.
Sharp Weitlaner Retractor.
Baby Weitlaner retractor, blunt, 4".
Medicine Products: